Drug intelligence / Profile preview

TAP-1503

Development stage: Unknown
Lead developer: Shanghai Thederma
Modality: Small Molecules
Administration: Topical

Overview

TAP-1503 is a small molecule drug developed as a topical cream for the treatment of atopic dermatitis. It acts as an aryl hydrocarbon receptor (AHR) modulator, targeting immune and inflammatory pathways relevant to skin diseases. The drug has been primarily developed by Shanghai Thederma Pharmaceuticals and is being evaluated in phase 3 clinical trials for efficacy and safety in patients aged two years and older with atopic dermatitis. Its highest development status is NDA/BLA submission in China, where it has also received priority review status[1][2][7].

Other names: TAP-1503TAP1503TAP 1503

Targets

AHR (Aryl hydrocarbon receptor)

Beyond the preview

Go deeper on TAP-1503.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TAP-1503.

Explore the full profile